PLCB4

Summary

PLCB4 (phospholipase C beta 4, HGNC:9059) is a protein-coding gene on chromosome 20p12.3-p12.2, encoding 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (Q15147). Activated phosphatidylinositol-specific phospholipase C enzymes catalyze the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) involved in G-protein coupled receptor signaling pathways.

The protein encoded by this gene catalyzes the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction uses calcium as a cofactor and plays an important role in the intracellular transduction of many extracellular signals in the retina. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5332 — RefSeq curated summary.

At a glance

• Gene–disease (curated): auriculocondylar syndrome 2 (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 7
• Clinical variants (ClinVar): 387 total — 16 pathogenic, 11 likely-pathogenic
• Phenotypes (HPO): 66
• MANE Select transcript: NM_001377142

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9059
Approved symbol	PLCB4
Name	phospholipase C beta 4
Location	20p12.3-p12.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000101333
Ensembl biotype	protein_coding
OMIM	600810
Entrez	5332

Gene structure

Transcript identifiers

Ensembl transcripts: 71 — 49 protein_coding, 9 retained_intron, 8 nonsense_mediated_decay, 5 protein_coding_CDS_not_defined

ENST00000278655, ENST00000378473, ENST00000378493, ENST00000378501, ENST00000407043, ENST00000414679, ENST00000416836, ENST00000437503, ENST00000441846, ENST00000464199, ENST00000473151, ENST00000482123, ENST00000492632, ENST00000684997, ENST00000685110, ENST00000685148, ENST00000685298, ENST00000685310, ENST00000685446, ENST00000685482, ENST00000685568, ENST00000685823, ENST00000685859, ENST00000686117, ENST00000686163, ENST00000686253, ENST00000686313, ENST00000686532, ENST00000686584, ENST00000686789, ENST00000686871, ENST00000686893, ENST00000686976, ENST00000687147, ENST00000687299, ENST00000687446, ENST00000687765, ENST00000688049, ENST00000688325, ENST00000688465, ENST00000688656, ENST00000688837, ENST00000689010, ENST00000689392, ENST00000689588, ENST00000689910, ENST00000689976, ENST00000690729, ENST00000690960, ENST00000691007, ENST00000691048, ENST00000691112, ENST00000692085, ENST00000692395, ENST00000693005, ENST00000693090, ENST00000693160, ENST00000693492, ENST00000693502, ENST00000693544, ENST00000693752, ENST00000920652, ENST00000920653, ENST00000920654, ENST00000946817, ENST00000946818, ENST00000946819, ENST00000946820, ENST00000946821, ENST00000946822, ENST00000946823

RefSeq mRNA: 8 — MANE Select: NM_001377142 NM_000933, NM_001172646, NM_001377134, NM_001377135, NM_001377136, NM_001377142, NM_001377143, NM_182797

CCDS: CCDS13104, CCDS13105, CCDS54447, CCDS93005

Canonical transcript exons

ENST00000378473 — 40 exons

Exon	Start	End
ENSE00001357789	9217390	9217452
ENSE00001682909	9069087	9069206
ENSE00001741784	9096287	9096342
ENSE00003461608	9453347	9453462
ENSE00003463323	9393588	9393678
ENSE00003468763	9411037	9411088
ENSE00003468971	9407917	9408058
ENSE00003481247	9338008	9338067
ENSE00003487058	9473279	9473365
ENSE00003488967	9444178	9444243
ENSE00003494218	9457414	9457489
ENSE00003497558	9307800	9307898
ENSE00003503832	9423748	9423952
ENSE00003507077	9435560	9435648
ENSE00003507933	9421297	9421461
ENSE00003522644	9373047	9373104
ENSE00003523380	9365461	9365514
ENSE00003525699	9476717	9476753
ENSE00003526265	9371214	9371295
ENSE00003553442	9337126	9337206
ENSE00003561687	9390531	9390615
ENSE00003565542	9395523	9395618
ENSE00003568651	9380054	9380162
ENSE00003580943	9468571	9468672
ENSE00003582948	9409057	9409181
ENSE00003588375	9372303	9372403
ENSE00003598957	9338894	9339037
ENSE00003609650	9405313	9405348
ENSE00003621309	9437002	9437152
ENSE00003630301	9459635	9459810
ENSE00003631620	9401490	9401590
ENSE00003639797	9443981	9444030
ENSE00003640552	9472790	9472847
ENSE00003642199	9408633	9408717
ENSE00003649758	9387463	9387556
ENSE00003654783	9362896	9362975
ENSE00003655280	9389879	9389958
ENSE00003655995	9384201	9384411
ENSE00003670085	9419807	9419909
ENSE00003906295	9478921	9480808

Expression profiles

Bgee: expression breadth ubiquitous, 273 present calls, max score 97.37.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.7461 / max 1049.4137, expressed in 1128 samples.

FANTOM5 promoters (20 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183442	5.2154	996
183444	4.0258	434
183443	2.8306	407
183445	1.7690	311
183447	1.3677	398
183439	1.3170	582
183441	0.8541	389
183446	0.3953	184
183440	0.3345	218
183475	0.2825	111

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	97.37	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.18	gold quality
sural nerve	UBERON:0015488	95.30	gold quality
bronchial epithelial cell	CL:0002328	92.78	gold quality
cerebellar cortex	UBERON:0002129	92.10	gold quality
cerebellar hemisphere	UBERON:0002245	92.04	gold quality
cerebellum	UBERON:0002037	91.83	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.61	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.10	gold quality
epithelium of bronchus	UBERON:0002031	90.80	gold quality
colonic mucosa	UBERON:0000317	90.79	gold quality
bronchus	UBERON:0002185	90.38	gold quality
blood vessel layer	UBERON:0004797	90.14	gold quality
cerebellar vermis	UBERON:0004720	89.65	gold quality
colonic epithelium	UBERON:0000397	89.07	gold quality
pigmented layer of retina	UBERON:0001782	88.68	gold quality
retina	UBERON:0000966	88.65	gold quality
pons	UBERON:0000988	88.41	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.06	gold quality
corpus epididymis	UBERON:0004359	87.52	gold quality
rectum	UBERON:0001052	87.32	gold quality
urethra	UBERON:0000057	87.10	gold quality
right uterine tube	UBERON:0001302	87.01	gold quality
substantia nigra pars compacta	UBERON:0001965	86.73	gold quality
caput epididymis	UBERON:0004358	86.60	gold quality
choroid plexus epithelium	UBERON:0003911	86.57	gold quality
nasal cavity mucosa	UBERON:0001826	86.51	gold quality
buccal mucosa cell	CL:0002336	86.33	gold quality
mucosa of stomach	UBERON:0001199	85.91	gold quality

Single-cell (SCXA)

Detected in 12 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	702.22
E-MTAB-8410	yes	358.79
E-MTAB-10287	yes	66.73
E-MTAB-6701	yes	30.75
E-GEOD-137537	yes	16.30
E-ANND-3	yes	16.14
E-HCAD-25	yes	11.84
E-GEOD-81547	yes	11.74
E-ENAD-27	yes	10.26
E-HCAD-35	yes	9.72
E-GEOD-83139	yes	8.76
E-MTAB-10290	no	209.96

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTCF, PAX6, RORA

miRNA regulators (miRDB)

118 targeting PLCB4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-371A-3P	99.99	66.77	91
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-651-3P	99.94	73.48	5177

Literature-anchored findings (GeneRIF, showing 19)

• Presence of PLCbeta(4) in the heart and in HL-1 cardiomyocytes showing a different species-dependent pattern of expression of the PLCbeta((1-4)) transcripts. (PMID:19856080)
• The significant contribution of PSMD3-CSF3 and PLCB4 loci to the regulation of neutrophil count, is demonstrated. (PMID:20172861)
• The phenotypic variability of auriculocondylar syndrome suggests that mutations in this pathway, especially those affecting core signaling molecules such as PLCB4 and GNAI3, should be considered as potential candidates for other ear and jaw malformations. (PMID:22560091)
• PLCbeta4 is enriched at the plasma membrane. (PMID:23006664)
• Auriculocondylar syndrome is caused by PLCB4 mutations inherited not only in an autosomal dominant manner (catalytic domain missense mutations) but also inherited as autosomal recessive (complete loss of function). (PMID:23913798)
• This study demonistrated by Gene expression profile that PLCB4 upregulaion in fibroblasts of Huntington’s disease patients. (PMID:24296361)
• Phospholipase C-beta1 and beta4 contribute to non-genetic cell-to-cell variability in histamine-induced calcium signals in HeLa cells. (PMID:24475116)
• Polymorphism of the PLCB4/B1 genes might be involved in the coronary artery aneurysm pathogenesis of Kawasaki disease. (PMID:26434682)
• Dysregulation of primary PLC signaling is linked to several brain disorders including epilepsy, schizophrenia, bipolar disorder, Huntington’s disease, depression and Alzheimer’s disease. (Review) (PMID:26639088)
• recurrent mutation in PLCB4 is associated with uveal melanoma. (PMID:26683228)
• Our observations of this case further delineate the phenotype of ACS associated with autosomal recessive PLCB4 loss-of-function mutations, underscoring gastrointestinal dysfunction and severe sleep-related breathing abnormalities as additional features when compared to patients with heterozygous mutations with a presumed dominant negative effect. (PMID:27007857)
• PLCB4 copy gain and PLCB4 overexpression is associated with gastrointestinal stromal tumors. (PMID:28212550)
• Novel pathogenic variants in PLCB4 have been found in two of three index patients with typical Auriculocondylar syndrome. (PMID:28328130)
• Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients. (PMID:31614358)
• A familial PLCB4 mutation causing auriculocondylar syndrome 2 with variable severity. (PMID:32201334)
• The Polymorphism at PLCB4 Promoter (rs6086746) Changes the Binding Affinity of RUNX2 and Affects Osteoporosis Susceptibility: An Analysis of Bioinformatics-Based Case-Control Study and Functional Validation. (PMID:34899595)
• Uveal melanoma-associated mutations in PLCbeta4 are constitutively activating and promote melanocyte proliferation and tumorigenesis. (PMID:34905385)
• Auriculocondylar syndrome 2 results from the dominant-negative action of PLCB4 variants. (PMID:35284927)
• Interaction between MARK3 (rs11623869), PLCB4 (rs6086746) and GEMIN2 (rs2277458) variants with bone mineral density and serum 25-hidroxivitamin D levels in Mexican Mestizo women. (PMID:38715801)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	PLCB4	ENSDARG00000100786
mus_musculus	Plcb4	ENSMUSG00000039943
rattus_norvegicus	Plcb4	ENSRNOG00000033119
drosophila_melanogaster	norpA	FBGN0262738
caenorhabditis_elegans		WBGENE00001177

Paralogs (14): PLCH1 (ENSG00000114805), PLCD4 (ENSG00000115556), PLCL1 (ENSG00000115896), PLCG1 (ENSG00000124181), PLCB2 (ENSG00000137841), PLCE1 (ENSG00000138193), PLCZ1 (ENSG00000139151), PLCH2 (ENSG00000149527), PLCB3 (ENSG00000149782), PLCL2 (ENSG00000154822), PLCD3 (ENSG00000161714), PLCB1 (ENSG00000182621), PLCD1 (ENSG00000187091), PLCG2 (ENSG00000197943)

Protein

Protein identifiers

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 — Q15147 (reviewed: Q15147)

Alternative names: Phosphoinositide phospholipase C-beta-4, Phospholipase C-beta-4

All UniProt accessions (28): Q15147, A0A7P0MRI8, A0A8I5KPD4, A0A8I5KPQ9, A0A8I5KQ87, A0A8I5KQF5, A0A8I5KQI1, A0A8I5KQZ0, A0A8I5KR92, A0A8I5KRA0, A0A8I5KRK2, A0A8I5KRP3, A0A8I5KS50, A0A8I5KVM8, A0A8I5KW09, A0A8I5KWR8, A0A8I5KX58, A0A8I5KX82, A0A8I5KXD7, A0A8I5KXT9, A0A8I5KXW3, A0A8I5KYY7, A0A8I5QJ53, A0A8I5QJE7, A0A8I5QL35, A0A8J8Z831, B1AJW1, B1AJW3

UniProt curated annotations — full annotation on UniProt →

Function. Activated phosphatidylinositol-specific phospholipase C enzymes catalyze the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) involved in G-protein coupled receptor signaling pathways. PLCB4 is a direct effector of the endothelin receptor signaling pathway that plays an essential role in lower jaw and middle ear structures development.

Subcellular location. Cell membrane.

Tissue specificity. Preferentially expressed in the retina.

Disease relevance. Auriculocondylar syndrome 2A (ARCND2A) [MIM:614669] An autosomal dominant form of auriculocondylar syndrome, a craniofacial malformation syndrome characterized by variable mandibular anomalies, including mild to severe micrognathia, temporomandibular joint ankylosis, cleft palate, and a characteristic ear malformation that consists of separation of the lobule from the external ear, giving the appearance of a question mark (question-mark ear). Other frequently described features include prominent cheeks, cupped and posteriorly rotated ears, preauricular tags, and microstomia. Glossoptosis, masticatory abnormalities, orthodontic problems, and malocclusion occur in a majority of affected subjects. The disease is caused by variants affecting the gene represented in this entry. Auriculocondylar syndrome 2B (ARCND2B) [MIM:620458] An autosomal recessive form of auriculocondylar syndrome, a craniofacial malformation syndrome characterized by variable mandibular anomalies, including mild to severe micrognathia, temporomandibular joint ankylosis, cleft palate, and a characteristic ear malformation that consists of separation of the lobule from the external ear, giving the appearance of a question mark (question-mark ear). Other frequently described features include prominent cheeks, cupped and posteriorly rotated ears, preauricular tags, and microstomia. Glossoptosis, masticatory abnormalities, orthodontic problems, and malocclusion occur in a majority of affected subjects. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (4)

UniProt ID	Names	Canonical?
Q15147-1	2	yes
Q15147-2	1
Q15147-4	3
Q15147-5	4

RefSeq proteins (8): NP_000924, NP_001166117, NP_001364063, NP_001364064, NP_001364065, NP_001364071, NP_001364072, NP_877949 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000008	C2_dom	Domain
IPR000909	PLipase_C_PInositol-sp_X_dom	Domain
IPR001192	PI-PLC_fam	Family
IPR001711	PLipase_C_Pinositol-sp_Y	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR014815	PLC-beta_C	Domain
IPR016280	PLC-beta	Family
IPR017946	PLC-like_Pdiesterase_TIM-brl	Homologous_superfamily
IPR035892	C2_domain_sf	Homologous_superfamily
IPR037862	PLC-beta_PH	Domain
IPR042531	PLC-beta_C_sf	Homologous_superfamily
IPR053945	PLCB1-4-like_EFh	Domain

Pfam: PF00168, PF00387, PF00388, PF08703, PF17787, PF22631

Enzyme classification (BRENDA):

• EC 3.1.4.11 — phosphoinositide phospholipase C (BRENDA: 69 organisms, 175 substrates, 159 inhibitors, 27 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

5 substrates with measured Km, best-characterized 5. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
1-PHOSPHATIDYL-1D-MYO-INOSITOL 4,5-BISPHOSPHATE	0.006–0.45	8
PHOSPHATIDYLINOSITOL	0.012–100	7
1-PHOSPHATIDYL-1D-MYO-INOSITOL	0.058–18.7	6
PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE	0.031–0.182	3
PHOSPHATIDYLINOSITOL 4-PHOSPHATE	0.031	1

Catalyzed reactions (Rhea), 2 shown:

• a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2-diacyl-sn-glycerol + H(+) (RHEA:33179)
• a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O = 1D-myo-inositol 1-phosphate + a 1,2-diacyl-sn-glycerol + H(+) (RHEA:43484)

UniProt features (40 total): sequence variant 15, sequence conflict 5, compositionally biased region 4, splice variant 4, domain 3, region of interest 3, active site 2, modified residue 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15147-F1	86.03	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 328; 375

Post-translational modifications (2): 2, 886

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-112043	PLC beta mediated events
R-HSA-1855204	Synthesis of IP3 and IP4 in the cytosol
R-HSA-416476	G alpha (q) signalling events

MSigDB gene sets: 407 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, BROWNE_HCMV_INFECTION_6HR_DN, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN, SASAI_TARGETS_OF_CXCR6_AND_PTCH1_UP, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GGGCATT_MIR365, DAWSON_METHYLATED_IN_LYMPHOMA_TCL1, GOBP_MAINTENANCE_OF_LOCATION, ROZANOV_MMP14_TARGETS_UP, KEGG_HUNTINGTONS_DISEASE, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS

GO Biological Process (10): G protein-coupled receptor signaling pathway (GO:0007186), lipid catabolic process (GO:0016042), phosphatidylinositol metabolic process (GO:0046488), phosphatidylinositol-mediated signaling (GO:0048015), release of sequestered calcium ion into cytosol (GO:0051209), phospholipase C-activating endothelin receptor signaling pathway (GO:0160135), lipid metabolic process (GO:0006629), signal transduction (GO:0007165), intracellular signal transduction (GO:0035556), modulation of chemical synaptic transmission (GO:0050804)

GO Molecular Function (8): phosphatidylinositol-4,5-bisphosphate phospholipase C activity (GO:0004435), C-type glycerophospholipase activity (GO:0004629), calcium ion binding (GO:0005509), phosphatidylinositol phospholipase C activity (GO:0120548), protein binding (GO:0005515), phosphoric diester hydrolase activity (GO:0008081), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (11): cytosol (GO:0005829), plasma membrane (GO:0005886), nucleus (GO:0005634), smooth endoplasmic reticulum (GO:0005790), endomembrane system (GO:0012505), postsynaptic density (GO:0014069), membrane (GO:0016020), dendrite (GO:0030425), parallel fiber to Purkinje cell synapse (GO:0098688), postsynapse (GO:0098794), glutamatergic synapse (GO:0098978)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
G-protein mediated events	1
Inositol phosphate metabolism	1
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
signal transduction	2
C-type glycerophospholipase activity	2
synapse	2
G protein-coupled receptor activity	1
lipid metabolic process	1
catabolic process	1
phosphorus metabolic process	1
intracellular signal transduction	1
intercellular transport	1
calcium ion transmembrane import into cytosol	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
endothelin receptor signaling pathway	1
primary metabolic process	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
intracellular anatomical structure	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
glycerophospholipase activity	1
phosphoric diester hydrolase activity	1
metal ion binding	1
binding	1
phosphoric ester hydrolase activity	1
catalytic activity	1
cation binding	1
cytoplasm	1
membrane	1
cell periphery	1
intracellular membrane-bounded organelle	1
endoplasmic reticulum	1
vacuole	1
plasma membrane	1
asymmetric synapse	1
postsynaptic specialization	1
neuron projection	1
dendritic tree	1

Protein interactions and networks

STRING

1440 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLCB4	GNA11	P29992	736
PLCB4	GNAQ	P50148	736
PLCB4	CYSLTR2	Q9NS75	721
PLCB4	EIF1AX	P47813	671
PLCB4	OPN4	Q9UHM6	540
PLCB4	GNAI3	P08754	514
PLCB4	GRM1	Q13255	511
PLCB4	TRPC6	Q9Y210	492
PLCB4	PLCB3	Q01970	475
PLCB4	ITPR1	Q14643	460
PLCB4	ADCY5	O95622	454
PLCB4	GNA14	O95837	452
PLCB4	BAP1	Q92560	445
PLCB4	PRKCG	P05129	440
PLCB4	ZNF37A	P17032	429

IntAct

116 interactions, top by confidence:

A	B	Type	Score
PLCB4	REL	psi-mi:“MI:0915”(physical association)	0.560
REL	PLCB4	psi-mi:“MI:0915”(physical association)	0.560
PLCB4	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
PLCB4	PDZD7	psi-mi:“MI:0407”(direct interaction)	0.440
LNX2	PLCB4	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	SNTB1	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	ARHGEF11	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	ARHGEF12	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	MAST1	psi-mi:“MI:0407”(direct interaction)	0.440
MAGI2	PLCB4	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	DLG2	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	HTRA1	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	GORASP2	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	NOS1	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	SCRIB	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	SNTA1	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	PDZRN3	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	GORASP1	psi-mi:“MI:0407”(direct interaction)	0.440
GOPC	PLCB4	psi-mi:“MI:0407”(direct interaction)	0.440
FRMPD2	PLCB4	psi-mi:“MI:0407”(direct interaction)	0.440
PLCB4	LNX1	psi-mi:“MI:0407”(direct interaction)	0.440
TAMALIN	PLCB4	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (39): REL (Two-hybrid), PLCB4 (Two-hybrid), PLCB4 (Affinity Capture-RNA), PLCB4 (Synthetic Lethality), MEOX2 (Two-hybrid), PLCB4 (Affinity Capture-MS), PLCB4 (Proximity Label-MS), PLCB4 (Proximity Label-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS), PLCB4 (Affinity Capture-MS)

ESM2 similar proteins: A0A075QQ08, A0A1D8EJF9, A0A1U8F5V2, A0A1U8GR65, A0A2J6L8Y7, A0A3Q7FGP1, A0A3Q7I7R4, A0A445AGS0, A0A7U2QYM2, A7KWF8, C6ZJZ3, C7SG33, D3UW26, K0P2S0, M1J8U6, M1JJT8, O23252, O60573, O77210, O81481, O81482, P0DXI0, P0DXI5, P10687, P10894, P29557, P48599, P48600, P48722, P97789, Q03389, Q0GRC4, Q15147, Q28GH3, Q3UTA9, Q4QXS7, Q4VQY1, Q4VQY3, Q5GFD8, Q642Q1

Diamond homologs: A2AP18, A3KGF7, A5D6R3, G5EBH0, G5EFI8, O75038, O89040, P10687, P10688, P10894, P10895, P21671, P25455, P51178, P51432, Q00722, Q01970, Q07722, Q15111, Q15147, Q1RML2, Q2VRL0, Q32NH8, Q3USB7, Q4KWH5, Q4KWH8, Q4R6L3, Q5FX52, Q5RET0, Q62688, Q62711, Q6NMA7, Q7YRU3, Q86YW0, Q8K2J0, Q8K394, Q8K3R3, Q8K4D7, Q8K4S1, Q8L706

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 77 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Ras activation upon Ca2+ influx through NMDA receptor	6	64.6×	2e-08
Unblocking of NMDA receptors, glutamate binding and activation	6	61.6×	2e-08
Negative regulation of NMDA receptor-mediated neuronal transmission	6	61.6×	2e-08
Long-term potentiation	6	53.9×	3e-08
Assembly and cell surface presentation of NMDA receptors	11	52.7×	8e-15
Dopamine Neurotransmitter Release Cycle	5	46.8×	2e-06
Neurexins and neuroligins	12	44.6×	5e-15
Protein-protein interactions at synapses	7	35.1×	3e-08

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	10	76.5×	2e-14
receptor clustering	7	57.5×	7e-09
protein localization to synapse	5	50.4×	3e-06
regulation of postsynaptic membrane neurotransmitter receptor levels	7	45.6×	3e-08
protein-containing complex assembly	9	13.5×	2e-06
cell-cell adhesion	10	13.4×	4e-07
chemical synaptic transmission	8	8.1×	3e-04
nervous system development	8	4.8×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

387 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	16
Likely pathogenic	11
Uncertain significance	182
Likely benign	36
Benign	90

Top pathogenic / likely-pathogenic (27)

Variant ID	HGVS	Classification
1706453	NM_001377142.1(PLCB4):c.2814+1G>C	Pathogenic
209128	NM_001377142.1(PLCB4):c.986A>C (p.Asn329Thr)	Pathogenic
2875083	NM_001377142.1(PLCB4):c.3031_3032del (p.Glu1011fs)	Pathogenic
31637	NM_001377142.1(PLCB4):c.1904A>G (p.Tyr635Cys)	Pathogenic
31638	NM_001377142.1(PLCB4):c.986A>G (p.Asn329Ser)	Pathogenic
31639	NM_001377142.1(PLCB4):c.1898G>A (p.Arg633His)	Pathogenic
31640	NM_001377142.1(PLCB4):c.1897C>T (p.Arg633Cys)	Pathogenic
31641	NM_001377142.1(PLCB4):c.1984A>C (p.Asn662His)	Pathogenic
3248283	NC_000020.10:g.(?7812350)(10654278_?)del	Pathogenic
4082118	NM_001377142.1(PLCB4):c.1918del (p.Arg640fs)	Pathogenic
633597	NM_001377142.1(PLCB4):c.1924G>T (p.Asp642Tyr)	Pathogenic
64692	NM_001377142.1(PLCB4):c.1898G>T (p.Arg633Leu)	Pathogenic
64693	NM_001377142.1(PLCB4):c.1073A>T (p.Glu358Val)	Pathogenic
64694	NM_001377142.1(PLCB4):c.1078G>A (p.Asp360Asn)	Pathogenic
64695	NM_001377142.1(PLCB4):c.1079A>T (p.Asp360Val)	Pathogenic
64696	NM_001377142.1(PLCB4):c.1648-279_2051+1546del	Pathogenic
1030923	NM_001377142.1(PLCB4):c.1124A>G (p.His375Arg)	Likely pathogenic
1067926	NM_001377142.1(PLCB4):c.3409-1G>T	Likely pathogenic
2432743	NM_001377142.1(PLCB4):c.815_821del (p.Ile272fs)	Likely pathogenic
3342734	NM_001377142.1(PLCB4):c.21del (p.Phe7fs)	Likely pathogenic
3382174	NM_001377142.1(PLCB4):c.1057G>A (p.Gly353Ser)	Likely pathogenic
3767226	NM_001377142.1(PLCB4):c.1656dup (p.Thr553fs)	Likely pathogenic
3769206	NC_000020.10:g.(9319685_9343542)_(9346162_9351860)dup	Likely pathogenic
3777145	NM_001377142.1(PLCB4):c.1732T>C (p.Ser578Pro)	Likely pathogenic
382944	NM_001377142.1(PLCB4):c.453G>T (p.Trp151Cys)	Likely pathogenic
4294389	NM_001377142.1(PLCB4):c.1080C>G (p.Asp360Glu)	Likely pathogenic
451364	NM_001377142.1(PLCB4):c.1925A>T (p.Asp642Val)	Likely pathogenic

SpliceAI

5729 predictions. Top by Δscore:

Variant	Effect	Δscore
20:9307895:GGAG:G	donor_gain	1.0000
20:9307896:GAGG:G	donor_gain	1.0000
20:9307897:AGGT:A	donor_loss	1.0000
20:9307898:GGT:G	donor_loss	1.0000
20:9307899:G:T	donor_loss	1.0000
20:9307900:T:G	donor_loss	1.0000
20:9338063:CAAAG:C	donor_loss	1.0000
20:9338064:AAAGG:A	donor_loss	1.0000
20:9338066:AG:A	donor_loss	1.0000
20:9338067:GG:G	donor_loss	1.0000
20:9338068:G:A	donor_loss	1.0000
20:9338069:T:G	donor_loss	1.0000
20:9338877:T:TA	acceptor_gain	1.0000
20:9338879:T:TA	acceptor_gain	1.0000
20:9338882:A:AG	acceptor_gain	1.0000
20:9338883:C:G	acceptor_gain	1.0000
20:9338890:ACAG:A	acceptor_gain	1.0000
20:9338891:C:G	acceptor_gain	1.0000
20:9338892:A:AG	acceptor_gain	1.0000
20:9338892:AG:A	acceptor_gain	1.0000
20:9338892:AGG:A	acceptor_loss	1.0000
20:9338893:G:GT	acceptor_gain	1.0000
20:9338893:GG:G	acceptor_gain	1.0000
20:9338893:GGAT:G	acceptor_gain	1.0000
20:9338893:GGATC:G	acceptor_gain	1.0000
20:9339026:G:GT	donor_gain	1.0000
20:9339033:CTAAG:C	donor_loss	1.0000
20:9339035:AAG:A	donor_loss	1.0000
20:9339036:AG:A	donor_loss	1.0000
20:9339038:GTA:G	donor_loss	1.0000

AlphaMissense

8070 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:9365508:T:A	V166D	1.000
20:9371267:T:C	L186P	1.000
20:9372352:T:C	L212P	1.000
20:9380061:G:C	R251P	1.000
20:9384234:T:C	L296P	1.000
20:9384239:T:C	S298P	1.000
20:9384324:C:T	S326F	1.000
20:9384327:C:T	S327F	1.000
20:9384329:C:G	H328D	1.000
20:9384329:C:T	H328Y	1.000
20:9384330:A:G	H328R	1.000
20:9384330:A:T	H328L	1.000
20:9384331:T:A	H328Q	1.000
20:9384331:T:G	H328Q	1.000
20:9384334:C:A	N329K	1.000
20:9384334:C:G	N329K	1.000
20:9384338:T:C	Y331H	1.000
20:9384338:T:G	Y331D	1.000
20:9384342:T:A	L332H	1.000
20:9384342:T:C	L332P	1.000
20:9384355:G:C	Q336H	1.000
20:9384355:G:T	Q336H	1.000
20:9384357:T:C	F337S	1.000
20:9384369:C:T	S341F	1.000
20:9387464:T:C	C356R	1.000
20:9387466:T:G	C356W	1.000
20:9387468:T:A	V357D	1.000
20:9387470:G:A	E358K	1.000
20:9387471:A:T	E358V	1.000
20:9387472:A:C	E358D	1.000

dbSNP variants (sampled 300 via entrez): RS1000004620 (20:9342218 C>G), RS1000025087 (20:9156682 A>G), RS1000033742 (20:9470765 G>A,T), RS1000045426 (20:9258335 C>A), RS1000048714 (20:9429418 A>G), RS1000051425 (20:9478452 C>T), RS1000058443 (20:9432402 A>G), RS1000061228 (20:9334004 G>A), RS1000070565 (20:9113235 A>C), RS1000071617 (20:9468817 A>C,G), RS1000074388 (20:9069546 T>C), RS1000083722 (20:9107126 T>G), RS1000084628 (20:9245613 C>T), RS1000087870 (20:9383016 G>A), RS1000091908 (20:9334273 T>C)

Disease associations

OMIM: gene MIM:600810 | disease phenotypes: MIM:614669, MIM:602483, MIM:613722, MIM:118450, MIM:620458, MIM:143890, MIM:215045, MIM:155720

GenCC curated gene-disease

Disease	Classification	Inheritance
auriculocondylar syndrome 2	Strong	Autosomal dominant
auriculocondylar syndrome 2B	Strong	Autosomal recessive
auriculocondylar syndrome	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (2)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
auriculocondylar syndrome 2	Definitive	AD
auriculocondylar syndrome 2	Definitive	AR

Mondo (11): auriculocondylar syndrome 2 (MONDO:0013845), prostate cancer (MONDO:0008315), long QT syndrome (MONDO:0002442), auriculocondylar syndrome 1 (MONDO:0011234), auriculocondylar syndrome (MONDO:0000107), developmental and epileptic encephalopathy, 12 (MONDO:0013389), Alagille syndrome due to a JAG1 point mutation (MONDO:0016862), auriculocondylar syndrome 2B (MONDO:0957544), familial hypercholesterolemia (MONDO:0005439), chondrodysplasia Blomstrand type (MONDO:0008970), uveal melanoma (MONDO:0006486)

Orphanet (6): Auriculocondylar syndrome (Orphanet:137888), Familial prostate cancer (Orphanet:1331), Alagille syndrome due to a JAG1 point mutation (Orphanet:261619), Alagille syndrome (Orphanet:52), Blomstrand lethal chondrodysplasia (Orphanet:50945), Uveal melanoma (Orphanet:39044)

HPO phenotypes

66 total (30 of 66 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000040	Long penis
HP:0000160	Narrow mouth
HP:0000162	Glossoptosis
HP:0000171	Microglossia
HP:0000175	Cleft palate
HP:0000183	Tongue muscle weakness
HP:0000193	Bifid uvula
HP:0000256	Macrocephaly
HP:0000293	Full cheeks
HP:0000311	Round face
HP:0000324	Facial asymmetry
HP:0000341	Narrow forehead
HP:0000347	Micrognathia
HP:0000358	Posteriorly rotated ears
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000377	Abnormal pinna morphology
HP:0000384	Preauricular skin tag
HP:0000402	Stenosis of the external auditory canal
HP:0000506	Telecanthus
HP:0000508	Ptosis
HP:0000664	Synophrys
HP:0000678	Dental crowding
HP:0000689	Dental malocclusion
HP:0000729	Autistic behavior
HP:0001140	Limbal dermoid
HP:0001252	Hypotonia
HP:0001263	Global developmental delay

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000600_1	Neutrophil count	3.000000e-10
GCST003518_23	Daytime sleep phenotypes	6.000000e-07
GCST005023_39	Initial pursuit acceleration	4.000000e-07
GCST005026_13	Initial pursuit acceleration in psychotic disorders	9.000000e-08
GCST009391_1517	Metabolite levels	9.000000e-06
GCST009391_262	Metabolite levels	8.000000e-06
GCST010574_9	Evening vs. morning chronotype (self-assessed)	6.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0007828	daytime rest measurement
EFO:0008434	initial pursuit acceleration
EFO:0010417	triacylglycerol 52:5 measurement
EFO:0010426	triacylglycerol 54:8 measurement
EFO:0008328	chronotype measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C538270	Auriculo-condylar syndrome (supp.)
C537914	Chondrodysplasia, blomstrand type (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Phosphoinositide-specific phospholipase C

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	4
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	3
Tobacco Smoke Pollution	affects expression, decreases expression	3
trichostatin A	affects expression, increases expression	2
perfluorooctane sulfonic acid	decreases expression, affects expression, affects cotreatment	2
Nickel	decreases expression	2
Particulate Matter	decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate	affects cotreatment, affects expression	1
methylmercuric chloride	decreases expression	1
methylselenic acid	increases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	affects cotreatment, affects expression	1
zinc chromate	decreases expression, increases abundance	1
aflatoxin B2	increases methylation	1
diallyl trisulfide	increases expression	1
sphingosine 1-phosphate	decreases reaction, increases expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
2,2’,4,4’,5-brominated diphenyl ether	decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
perfluorobutanesulfonic acid	affects expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
Fingolimod Hydrochloride	decreases reaction, increases expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0L7	Ubigene HeLa PLCB4 KO	Cancer cell line	Female
CVCL_TE24	HAP1 PLCB4 (-) 1	Cancer cell line	Male
CVCL_TE25	HAP1 PLCB4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer